健民集团(600976) - 2025 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2025 was ¥892,084,313.18, a decrease of 8.04% compared to ¥970,121,135.45 in the same period last year[4] - Net profit attributable to shareholders increased by 10.70% to ¥110,177,463.41 from ¥99,523,950.19 year-on-year[4] - The net profit after deducting non-recurring gains and losses rose by 13.92% to ¥103,066,613.51 compared to ¥90,473,671.59 in the previous year[4] - Basic and diluted earnings per share increased by 12.31% to ¥0.73 from ¥0.65 year-on-year[5] - The net profit for Q1 2025 was CNY 111,038,979.32, an increase of 10.8% compared to CNY 100,197,440.85 in Q1 2024[21] - The operating profit for the period was CNY 124,818,633.75, up from CNY 109,605,709.99 in the previous year, reflecting a growth of approximately 13.3%[21] Cash Flow and Liquidity - The net cash flow from operating activities improved significantly, with a net outflow of ¥24,924,066.40, an improvement of 51.74% from a net outflow of ¥51,647,096.25 in the same period last year[4] - Cash and cash equivalents as of March 31, 2025, were RMB 272,043,058.16, compared to RMB 163,173,887.90 at the end of 2024[14] - Total cash and cash equivalents at the end of Q1 2025 were CNY 263,457,096.69, slightly up from CNY 263,195,877.53 at the end of Q1 2024[26] - Investment activities generated a net cash inflow of CNY 129,265,161.41, significantly higher than CNY 44,527,721.22 in Q1 2024[25] - The total cash outflow from financing activities was CNY 66,298,284.43, which is an increase from CNY 64,523,544.01 in the previous year[26] Assets and Liabilities - Total assets at the end of the reporting period were ¥4,277,683,209.72, showing a slight increase of 0.0013% from ¥4,277,629,406.13 at the end of the previous year[5] - Total liabilities decreased to RMB 1,717,304,107.60 from RMB 1,827,290,163.33, a reduction of 6.06%[16] - Total current assets amounted to RMB 2,663,539,066.72, an increase from RMB 2,601,436,202.31 at the end of 2024[15] - Accounts receivable increased to RMB 868,319,513.26 from RMB 807,667,332.99, reflecting a growth of 7.48%[15] - Total equity attributable to shareholders increased to RMB 2,545,483,050.29 from RMB 2,435,305,586.88, reflecting a growth of 4.52%[17] Operating Costs and Revenue Structure - Total operating costs for Q1 2025 were RMB 815,768,780.89, down 12.59% from RMB 932,864,246.14 in Q1 2024[20] - Operating costs included RMB 378,144,996.22 in cost of goods sold, a decrease of 32.36% from RMB 557,827,701.77 in the previous year[20] - The decline in operating revenue was primarily due to the optimization of the pharmaceutical business structure, leading to a decrease in pharmaceutical commercial income[5] - The increase in net profit was attributed to higher pharmaceutical industrial income and an improved revenue structure of leading products[5] - The company reported a net profit margin improvement due to reduced operating costs and expenses[20] Non-Recurring Gains and Future Outlook - The company reported non-recurring gains totaling ¥7,110,849.90 after tax, with significant contributions from government subsidies and other non-operating income[8] - Future outlook includes potential market expansion and new product development initiatives[20] - Research and development expenses amounted to CNY 21,006,582.52, compared to CNY 22,951,668.26 in the same quarter last year, indicating a decrease of about 8.5%[21] - The total revenue from operating activities was CNY 908,797,546.00, down from CNY 965,139,178.41 in Q1 2024, representing a decline of approximately 5.8%[24]